About ClearIt

ClearIt, LLC, a Delaware limited liability company was founded in 2013 by Dr. James W. Winkelman and Martin E. Schmieg. The Company’s mission is to design, develop and market the first effective, painless, single treatment tattoo ERASER™ system – approaching 100% particle removal from the skin while safely avoiding current potential laser removal side-effects of scaring, skin color bleaching, shadow tattoos or absorption by the body of harmful mineral or chemical elements.

Key Executives

Martin Schmieg, “C” level executive since 1992 leading startup and development stage companies Cytometrics, Inc., Advanced Bionics Corporation, SIRNA Therapeutics, Inc., Isolagen, Inc., Freedom-2, Inc., and NeoStem, Inc. Early career experience with Boekel Scientific and E. Merck. CPA and guest lecturer at MIT and the University of Pennsylvania, Wharton School of Business

James W. Winkelman, M.D., Professor Emeritus of Pathology at Harvard Medical School and former Director of Clinical Laboratories of Brigham and Women’s Hospital. Founder of Cytometrics, Inc., Continuous Monitoring Calibration Systems, LLC, and Cell Imaging Systems, LLC. Dr. Winkelman is a graduate from John’s Hopkins Medical School.